Capital Investment Services Of America Has Trimmed Its Idexx Laboratories (IDXX) Position; Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Shorts Increased By 19%

December 16, 2017 - By Winifred Garcia

Capital Investment Services Of America Inc decreased Idexx Laboratories Inc (IDXX) stake by 92.46% reported in 2017Q2 SEC filing. Capital Investment Services Of America Inc sold 66,878 shares as Idexx Laboratories Inc (IDXX)’s stock rose 13.64%. The Capital Investment Services Of America Inc holds 5,450 shares with $880,000 value, down from 72,328 last quarter. Idexx Laboratories Inc now has $13.66B valuation. The stock increased 0.87% or $1.35 during the last trading session, reaching $156.6. About 1.05 million shares traded or 107.28% up from the average. IDEXX Laboratories, Inc. (NASDAQ:IDXX) has risen 83.30% since December 16, 2016 and is uptrending. It has outperformed by 66.60% the S&P500.

Ampio Pharmaceuticals Incorporated (NYSEAMERICAN:AMPE) had an increase of 19% in short interest. AMPE’s SI was 5.08M shares in December as released by FINRA. Its up 19% from 4.26M shares previously. With 1.36M avg volume, 4 days are for Ampio Pharmaceuticals Incorporated (NYSEAMERICAN:AMPE)’s short sellers to cover AMPE’s short positions. The stock decreased 6.44% or $0.15 during the last trading session, reaching $2.18. About 2.42 million shares traded or 85.38% up from the average. Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) has declined 79.44% since December 16, 2016 and is downtrending. It has underperformed by 96.14% the S&P500.

Investors sentiment decreased to 0.55 in Q2 2017. Its down 0.05, from 0.6 in 2017Q1. It fall, as 14 investors sold Ampio Pharmaceuticals, Inc. shares while 16 reduced holdings. 11 funds opened positions while 7 raised stakes. 8.49 million shares or 29.31% less from 12.01 million shares in 2017Q1 were reported. Moreover, Brown Advisory has 0% invested in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). Vanguard Gru, Pennsylvania-based fund reported 1.44M shares. Goldman Sachs Gru Inc invested in 283,490 shares or 0% of the stock. Guggenheim Cap Ltd Limited Liability Company has invested 0% in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). Susquehanna Gru Llp has invested 0% in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). Noven Grp Inc has invested 0.08% in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). Moreover, Oppenheimer And has 0% invested in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). Cypress Capital Management Ltd (Wy) has 0% invested in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) for 72,000 shares. Wells Fargo & Mn holds 18,283 shares. Lmr Ptnrs Llp stated it has 0.01% of its portfolio in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). The New York-based Knoll Cap Ltd Partnership has invested 1.79% in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE). California Public Employees Retirement System, a California-based fund reported 20,500 shares. Meeder Asset Mgmt Inc reported 2,598 shares. Private Advisor Grp Limited Company holds 0% in Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) or 12,605 shares. Pnc Svcs Grp Inc stated it has 13,659 shares.

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company has market cap of $165.55 million. The firm is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. It currently has negative earnings. The Company’s product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema.

Analysts await IDEXX Laboratories, Inc. (NASDAQ:IDXX) to report earnings on February, 1. They expect $0.73 EPS, up 25.86% or $0.15 from last year’s $0.58 per share. IDXX’s profit will be $63.67M for 53.63 P/E if the $0.73 EPS becomes a reality. After $0.79 actual EPS reported by IDEXX Laboratories, Inc. for the previous quarter, Wall Street now forecasts -7.59% negative EPS growth.

Since August 8, 2017, it had 0 buys, and 5 selling transactions for $17.16 million activity. AYERS JONATHAN W also sold $1.96 million worth of IDEXX Laboratories, Inc. (NASDAQ:IDXX) on Monday, August 28. The insider HENDERSON REBECCA M sold 5,156 shares worth $790,342.

Investors sentiment decreased to 0.86 in 2017 Q2. Its down 0.33, from 1.19 in 2017Q1. It fall, as 28 investors sold IDXX shares while 184 reduced holdings. 86 funds opened positions while 167 raised stakes. 76.34 million shares or 0.83% less from 76.98 million shares in 2017Q1 were reported. Granite Inv Ptnrs Limited Com has 0.04% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Cantab Ptnrs Ltd Liability Partnership holds 0% or 10,701 shares. Quantres Asset holds 1,400 shares. Secor Capital Advsrs Lp owns 22,178 shares. D E Shaw Incorporated holds 39,157 shares or 0.01% of its portfolio. Moreover, Congress Asset Mngmt Com Ma has 0.01% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Jane Street Group Inc Ltd Liability Corporation reported 24,773 shares or 0.01% of all its holdings. Stephens Investment Management Grp Ltd Company reported 280,554 shares. Jacobs Levy Equity Mngmt has 0.3% invested in IDEXX Laboratories, Inc. (NASDAQ:IDXX). The Vermont-based Trust Of Vermont has invested 0.01% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Dearborn Prns Limited Liability Company reported 0.05% in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Highland Management Limited Liability stated it has 1,710 shares or 0.02% of all its holdings. Toronto Dominion Comml Bank stated it has 0.02% of its portfolio in IDEXX Laboratories, Inc. (NASDAQ:IDXX). Comm Bancshares owns 2,726 shares. Peak6 Invs Limited Partnership has invested 0% in IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com